REPROCELL launches personalised iPSC production service

REPROCELL’s new service – Personal iPS – will generate individual specific induced pluripotent stem cells (iPSC). The company will start taking orders from this month (January 2021) in Japan and has also launched a new B2C website to promote this service, which is currently only available in Japan.

Personal iPS prepares and stores an individual’s iPSCs for the regenerative treatment of future illness or injury. Individual’s iPSCs are created from mature cells contained in their urine or dental pulp, using RNA reprogramming technology. The iPSCs are then stored at two locations in Japan and the United States to establish back-up in case of storage interruption in either facility

“We are incredibly excited to announce this new regenerative medicine initiative,” said Chikafumi Yokoyama, REPROCELL CEO. “We hope that Personal iPS will offer better health outcomes and quality of life for patients.”

Specific advantages of Personal iPS include: Painless collection of tissue for the creation of iPSCs; risk of transplant rejection is negated as the patient’s own tissues are used; iPSCs are stored at two sites in different countries in case of natural disasters, and foot-print-free mRNA technology is used, creating the highest-quality iPSCs.

Image credit: Riccardo Annandale


Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free